Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

ValiRx (VAL)

Price 1.675p on 21-11-2024 at 17:15:01
Change 0.00p 0%
Buy 1.75p
Sell 1.60p
Buy / Sell VAL Shares
Last Trade: Sell 3,649.00 at 1.67p
Day's Volume: 84,491
Last Close: 1.675p
Open: 1.675p
ISIN: GB00BLH13C52
Day's Range 1.675p - 1.675p
52wk Range: 1.225p - 13.125p
Market Capitalisation: £2m
VWAP: 1.648222p
Shares in Issue: 132m

Recent Trades History ValiRx (VAL)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 3,649 1.67p Ordinary
16:26:30 - 21-Nov-24
Sell* 17,126 1.6025p Ordinary
15:50:22 - 21-Nov-24
Sell* 1,000 1.60p Ordinary
13:42:59 - 21-Nov-24
Unknown* 50,000 1.675p Ordinary
11:51:42 - 21-Nov-24
Sell* 11,414 1.60p Ordinary
11:46:34 - 21-Nov-24
Sell* 1,302 1.62p Ordinary
11:22:45 - 21-Nov-24

Share Price History for ValiRx

Time period:
to
Date Open High Low Close Volume

Share News for ValiRx

IN BRIEF: ValiRx extends Ambrose Healthcare exclusivity agreement

20th Nov 2024 18:09

ValiRx PLC - Essex, England-based life sciences company - Says subsidiary ValiSeek Ltd has granted a six-month extension to Ambrose Healthcare Ltd offered under the exclusive option agreement inked in December 2023 to execute an exclusive sub-license of ValiSeek's VAL401 asset. Ambrose Healthcare now has a further six-month period during which it can choose to exercise the option. VAL401 is in development for the treatment of pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Read More

ValiRX adds to streak of deals with cancer cell test materials win

19th Nov 2024 11:39

(Alliance News) - ValiRX PLC announced on Tuesday it will provide more cancer cell detection materials to UK biotech firm Amply Discovery Ltd. Read More

AIM WINNERS & LOSERS: Woodbois subscription raises over GBP1 million

19th Nov 2024 10:39

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday. Read More

IN BRIEF: ValiRx notes subsidiary's shipment of patient derived cells

18th Nov 2024 12:21

ValiRx PLC - Hatfield Heath, England-based life sciences company focused on early-stage cancer therapeutics and women's health - Says subsidiary Inaphaea BioLabs Ltd has made the first customer shipment of its first batch of patient derived cells, which are provided as part of its new range of assay ready reagents. ValiRX says, though the order value is immaterial, it endorses the group's product offering and potential revenue source. Chief Executive Officer Mark Eccleston says: "This first sale of our new product range is a major milestone for our commercialisation efforts." Read More

EARNINGS: Kendrick Resources loss narrows; Emmerson CFO to depart

27th Sep 2024 13:56

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Friday and not separately reported by Alliance News: Read More

FTSE 100 Latest
Value8,149.27
Change64.20

Login to your account

Forgot Password?

Not Registered